International Journal of Medical and Pharmaceutical Research
2026, Volume-7, Issue 1 : 576-584
Original Article
Urinary Tract Infection in Children- Epidemiology, Clinical Features, Organisms and Their Antibiotic Susceptibility Pattern
 ,
Received
Dec. 15, 2025
Accepted
Jan. 6, 2026
Published
Jan. 16, 2026
Abstract

Background: Urinary tract infections (UTIs) are among the most common bacterial infections in children, resulting in significant morbidity if left untreated. Understanding the epidemiology, clinical features, causative organisms, and their antibiotic susceptibility patterns is crucial for effective management.

Objectives: To evaluate the demographic profile, clinical presentation, microbiological spectrum, and antimicrobial susceptibility patterns in pediatric UTIs at SDM Hospital, Dharwad.

Methods: A prospective observational study was conducted from August 2022 to August 2023. Children aged 1 month to 14 years with urine cultures yielding a single pathogen were included. Clinical features, risk factors, and ultrasonography findings were recorded. Urine samples were processed on CLED agar, and isolates were identified using standard microbiological techniques. Antimicrobial susceptibility was tested by the Modified Kirby–Bauer method, following CLSI guidelines.

Results: Among 102 children, 61.8% were male and 55.9% were aged 1–5 years. Fever (59.8%), dysuria (52.9%), and vomiting (42.1%) were common presentations. Upper UTIs accounted for 37.3% of cases and lower UTIs 62.7%. E. coli (64.7%) was the predominant pathogen, followed by Klebsiella pneumoniae (15.7%) and Pseudomonas aeruginosa (9.8%). High resistance was observed to ampicillin, cephalosporins, and cotrimoxazole, while nitrofurantoin, aminoglycosides, and meropenem showed better sensitivity. Gram-positive isolates (Enterococcus spp., CONS, MRSA) exhibited variable resistance, with linezolid and vancomycin remaining effective. Fungal UTIs (Candida tropicalis) were fully sensitive to all antifungals tested.

Conclusion: Pediatric UTIs in this cohort were largely caused by E. coli, with a significant proportion showing multidrug resistance. Culture-guided therapy is essential, and early diagnosis, identification of risk factors, and antimicrobial stewardship are critical to prevent treatment failure and resistance development

Keywords
INTRODUCTION

Urinary tract infection (UTI) is one of the most common bacterial infections encountered in the pediatric population and represents a significant cause of morbidity, especially in infants and young children. It is estimated that approximately 2–8% of children experience at least one episode of UTI during childhood, with higher prevalence in females after infancy and in males during the neonatal period due to congenital urinary tract anomalies [1,2]. Pediatric UTIs are of particular concern because of their potential to cause renal parenchymal damage, leading to long-term complications such as hypertension, proteinuria, and chronic kidney disease if not diagnosed and treated promptly [3].

 

The clinical presentation of UTI in children is often nonspecific and varies with age. While older children may present with classical symptoms such as dysuria, urinary frequency, urgency, and suprapubic pain, infants and young children frequently exhibit nonspecific manifestations including fever, vomiting, irritability, poor feeding, and failure to thrive [4]. This variability in presentation often leads to delayed diagnosis, increasing the risk of complications, particularly in cases of upper urinary tract infection (pyelonephritis) [5].

 

The etiology of pediatric UTIs is predominantly bacterial, with Gram-negative organisms accounting for the majority of infections. Escherichia coli remains the most common causative pathogen worldwide, responsible for 60–80% of cases, followed by Klebsiella pneumoniae, Proteus species, Enterococcus species, and non-fermenting Gram-negative bacilli [6,7]. In recent years, there has been a growing concern regarding the emergence of multidrug-resistant organisms, including extended-spectrum β-lactamase (ESBL)–producing and carbapenem-resistant Enterobacteriaceae (CRE), which significantly limit therapeutic options [8].

 

Antimicrobial resistance (AMR) among uropathogens has become a major global public health challenge, particularly in developing countries where empirical antibiotic therapy is commonly practiced [9]. Inappropriate antibiotic use, lack of antimicrobial stewardship, and easy over-the-counter availability of antibiotics have contributed to rising resistance rates, leading to increased treatment failure, prolonged hospital stays, and higher healthcare costs [10]. Surveillance of local antimicrobial susceptibility patterns is therefore essential to guide empirical therapy and optimize patient outcomes.

 

Risk factors such as bowel bladder dysfunction, constipation, recurrent diarrhea, congenital anomalies of the urinary tract, and recurrent UTIs play a crucial role in the pathogenesis and recurrence of pediatric UTIs [11,12]. Imaging modalities like ultrasonography help identify structural abnormalities and complications, aiding in risk stratification and long-term management [13].

 

Given the changing epidemiology of pediatric UTIs and the alarming rise in antimicrobial resistance, there is a pressing need for institution-based studies to evaluate the clinical profile, microbiological spectrum, and antibiotic susceptibility patterns of uropathogens. Such data are vital for formulating evidence-based empirical treatment guidelines and strengthening antimicrobial stewardship practices. The present study was therefore undertaken at a tertiary care teaching hospital in South India to assess the epidemiology, clinical features, causative organisms, and their antimicrobial susceptibility patterns in children with urinary tract infection.

 

MATERIALS AND METHODS

Study Design

This was a prospective observational study conducted to evaluate the microbiological profile and antimicrobial susceptibility patterns in pediatric urinary tract infections.

 

Study Setting

The study was carried out at SDM Hospital, Dharwad, a tertiary care teaching hospital catering to both outpatient and inpatient pediatric populations.

 

Study Period

The study was conducted over a period of one year, from August 2022 to August 2023.

 

Study Participants

Children aged 1 month to 14 years attending the outpatient department (OPD) or admitted to SDM Hospital, Dharwad, and suspected of having a urinary tract infection were screened for inclusion.

 

Inclusion Criteria

  • Children aged 1 month to 14 years
  • Urine culture yielding a single organism with a significant colony count
  • Patients attending OPD or admitted to SDM Hospital during the study period

 

Exclusion Criteria

  • Urine cultures showing polymicrobial growth
  • Infants aged less than 1 month

 

Sampling

Sampling Population

A total of 102 children who met the inclusion criteria were enrolled during the study period.

 

Sample Size Calculation

Sample size was calculated using the formula:

 

Where:

  • P = Prevalence from previous studies (8%)
  • Q = 100 − P (92%)
  • d = allowable error (6%)
  • Z = 1.96 for 95% confidence interval

The calculated sample size was 82. However, 102 eligible cases were included during the study period.

 

Sampling Technique

A convenience sampling technique was employed, enrolling all eligible participants who fulfilled the inclusion criteria during the study period.

 

Ethical Considerations

The study was approved by the Institutional Ethics Committee.

Written informed consent was obtained from parents or legal guardians prior to enrollment.

 

Study Procedure and Methodology

Collection and Processing of Urine Samples

Urine specimens were collected using appropriate methods based on age and clinical condition, including:

  • Clean-catch midstream urine
  • Catheterized urine
  • Suprapubic aspiration

Samples were processed using the semi-quantitative culture technique, employing a calibrated loop to inoculate urine onto Cystine Lactose Electrolyte Deficient (CLED) agar.

The inoculated plates were incubated at 37°C for 24 hours under aerobic conditions.

 

Identification of Isolates

Bacterial isolates were identified using standard microbiological techniques, including:

  • Colony morphology
  • Gram staining
  • Catalase and oxidase tests
  • In-house biochemical tests as required

 

Antimicrobial Susceptibility Testing

Antimicrobial susceptibility testing was performed using the Modified Kirby–Bauer disc diffusion method on Mueller–Hinton agar, following Clinical and Laboratory Standards Institute (CLSI) guidelines.

Interpretation of results was done according to CLSI zone diameter interpretative criteria.

 

Diagnosis and Follow-up

Diagnosis of urinary tract infection was based on significant colony count on urine culture. Patients were treated according to culture and sensitivity results and subsequently evaluated using appropriate imaging guidelines for further assessment and follow-up.

 

Data Collection

Data were collected prospectively using a pre-designed proforma after obtaining informed consent. Demographic details, clinical features, laboratory findings, culture results, and antimicrobial susceptibility patterns were recorded.

 

Definitions

  • Recurrent UTI: Two episodes of febrile urinary tract infection
  • Bowel bladder dysfunction: Voiding less than 3 times or more than 8 times per day, voiding holding maneuvers, straining, or poor urinary stream
  • Simple UTI: UTI with low-grade fever, dysuria, frequency, and urgency, without features of complicated UTI
  • Complicated UTI: Presence of fever >39°C, systemic toxicity, persistent vomiting, dehydration, or renal angle tenderness
  • Upper UTI: Infection involving kidneys and ureters (pyelonephritis), presenting with fever, flank pain, vomiting, lethargy, and malaise
  • Lower UTI: Infection involving bladder and urethra (cystitis), presenting with dysuria, urinary frequency, urgency, and suprapubic pain

 

Statistical Analysis

Data were entered into Microsoft Excel 2019 and analysed using IBM SPSS version 21.

  • Categorical variables were expressed as frequencies and percentages
  • Chi-square test was used to assess associations between categorical variables
  • A p-value < 0.05 was considered statistically significant

 

RESULTS AND OBSERVATIONS;

 

Table 1: Demographic Distribution of Study Participants (Age and Gender) (n = 102)

Variable

Category

Frequency

Percentage

Age Group

< 1 year

22

21.6

 

1–5 years

57

55.9

 

> 5 years

23

22.5

Gender

Male

63

61.8

 

Female

39

38.2

Total

 

102

100.0

 

Table 2: Various and multiple clinical features among study participants

Clinical features

Frequency

Percent

Fever

61

59.8

Vomiting

43

42.1

Dysuria

54

52.9

Urgency

20

19.6

Frequency

23

22.5

Irritability

40

39.2

Flank /back pain

23

22.5

Suprapubic pain

31

30.39

Poor feeding

37

36.3

Signs of

dehydration

 

22

 

21.5

 

Fig 1: Pie chart showing Upper and lower UTI distribution

 

Table 3: Distribution of Upper and Lower Urinary Tract Infections Across Different Age Groups and Gender (n = 102)

Type of UTI

Gender

< 1 year n (%)

1–5 years n (%)

> 5 years n (%)

Total n (%)

Upper UTI (n=38)

Male

11 (42.3)

14 (53.8)

1 (3.8)

26 (68.4)

 

Female

5 (41.6)

7 (58.3)

0 (0)

12 (31.6)

Lower UTI (n=64)

Male

4 (10.8)

22 (59.5)

11 (29.7)

37 (57.8)

 

Female

2 (7.4)

14 (51.8)

11 (40.7)

27 (42.2)

 

Table 4: Distribution of Risk Factors Among Study Participants Across Different Age Groups (n = 102)

Risk Factor

< 1 year n (%)

1–5 years n (%)

> 5 years n (%)

Total n (%)

p-value

Diarrhoea preceding week

15 (68.2)

18 (31.6)

0 (0.0)

33 (32.4)

0.001

Constipation

2 (9.1)

21 (36.8)

17 (73.9)

40 (39.2)

0.001

Posterior urethral valve (PUV)

3 (13.6)

1 (1.8)

0 (0.0)

4 (3.9)

0.028

Bowel bladder dysfunction (BBD)

0 (0.0)

18 (66.6)

9 (33.3)

27 (26.4)

0.098

Recurrent UTI

9 (40.9)

11 (19.3)

5 (21.7)

25 (24.5)

0.127

 

Table 5: Ultrasonography (USG) Findings and Clinical Classification of UTI Among Study Participants (n = 102)

Parameter

Category

Frequency

Percentage

USG Findings

Normal

53

52.0

 

Abnormal

33

32.4

 

Not done

16

15.7

Abnormal USG Findings(n = 33)

Cystitis

17

51.5

 

Hydroureteronephrosis

11

33.3

 

Prominent renal pelvis without hydronephrosis

5

15.1

Type of UTI

Complicated UTI

 

Uncomplicated UTI

Percentages for abnormal USG findings are calculated out of total abnormal scans (n = 33).

 

Fig 2: Bar graph showing frequency of various organisms isolated from patients (n = 102)

 

Chi square = 36.743, P value = 0.185 (NS)

Fig 3 : Multiple bar graph showing frequency of various organism isolated in different age group

 

Table: 6 Antibiotic Resistance and Sensitivity Patterns of Isolated Organisms (%)

  1. Antibiotic Resistance Pattern (%)

Organism

AK

AMP

FEP

FOX

CRO

CIP

SXT

NOR

AMC

CAZ

CTX

CXM

GEN

NIT

PTZ

CFM

NA

CF

CST

MEM

CFS

TGC

E. coli

8.9

95.6

86.7

68.9

95.6

82.2

73.3

87.7

64.5

95.6

97.8

97.8

40.0

42.2

57.8

97.8

97.8

97.8

66.7

57.8

64.4

53.4

E. coli (CRE)

92.3

100

100

100

100

100

92.3

100

100

100

100

100

92.3

53.8

100

100

100

100

53.8

100

92.3

38.5

K. pneumoniae

38.9

94.4

83.3

66.7

66.7

66.7

44.4

50.0

66.7

72.2

100

94.4

33.3

55.5

55.6

100

55.6

100

66.7

72.2

62.3

55.6

Enterococcus spp.

Pseudomonas aeruginosa

0

100

0

100

100

33.3

100

100

100

0

100

100

33.3

100

66.7

100

100

100

33.3

0

0

100

 

  1. Antibiotic Sensitivity Pattern (%)

Organism

AK

AMP

FEP

FOX

CRO

CIP

SXT

NOR

AMC

CAZ

CTX

CXM

GEN

NIT

PTZ

CFM

NA

CF

CST

MEM

CFS

TGC

E. coli

91.1

4.4

13.3

31.1

4.4

17.8

26.7

13.3

35.5

4.4

2.2

2.2

60.0

57.8

42.2

2.2

2.2

2.2

33.3

42.2

35.6

46.6

E. coli (CRE)

7.7

0

0

0

0

0

7.7

0

0

0

0

0

7.7

46.2

0

0

0

0

46.2

0

7.7

61.5

K. pneumoniae

61.1

5.6

16.7

33.3

33.3

33.3

55.6

50.0

33.3

27.8

0

5.6

66.7

44.5

44.4

0

44.4

0

33.3

27.8

37.7

44.4

Non-fermenting GNB

33.3

0

33.3

0

66.7

66.7

66.7

0

0

33.3

0

0

66.7

0

0

0

0

0

33.3

33.3

33.3

0

Pseudomonas aeruginosa

100

0

100

0

0

66.7

0

0

0

100

0

0

66.7

0

33.3

0

0

0

66.7

100

100

0

 

Table: 7 Antibiotic Resistance and Sensitivity Patterns of Gram-Positive Isolates (%)

  1. Antibiotic Resistance Pattern (%)

Organism

ERY

GEN

LZD

PEN

TGC

TEC

CIP

NIT

LEV

TET

VAN

DAP

CLI

RIF

SXT

OXA

FOX

Enterococcus faecalis

66.7

66.7

0.0

33.3

0.0

0.0

100.0

0.0

100.0

100.0

0.0

0.0

Enterococcus species

75.0

75.0

0.0

25.0

0.0

0.0

100.0

0.0

100.0

100.0

75.0

100.0

CONS

100.0

100.0

100.0

100.0

0.0

100.0

100.0

0.0

100.0

100.0

100.0

100.0

100.0

100.0

100.0

0.0

Staphylococcus aureus (MRSA)

100.0

100.0

0.0

100.0

0.0

0.0

0.0

0.0

100.0

100.0

0.0

100.0

0.0

100.0

100.0

0.0

Streptococcus species

100.0

100.0

0.0

100.0

0.0

0.0

100.0

100.0

100.0

100.0

0.0

100.0

100.0

100.0

100.0

100.0

 

 

  1. Antibiotic Sensitivity Pattern (%)

Organism

ERY

GEN

LZD

PEN

TGC

TEC

CIP

NIT

LEV

TET

VAN

DAP

Enterococcus faecalis

33.3

33.3

100.0

66.7

100.0

100.0

0.0

100.0

0.0

0.0

100.0

100.0

Enterococcus species

25.0

25.0

100.0

75.0

100.0

100.0

0.0

100.0

0.0

0.0

25.0

0.0

 

Table:8 Antibiotic Sensitivity Patterns of Gram-Positive Isolates (%)

  1. Antibiotic Sensitivity Pattern – Panel 1

Organism

Benzyl-Penicillin

Erythromycin

Linezolid

Teicoplanin

Tigecycline

Gentamicin

Ciprofloxacin

Levofloxacin

Nitrofurantoin

Tetracycline

CONS

0.0

0.0

0.0

0.0

100.0

0.0

0.0

0.0

100.0

0.0

Staphylococcus aureus (MRSA)

0.0

0.0

100.0

100.0

100.0

0.0

100.0

0.0

100.0

0.0

Streptococcus species

0.0

0.0

100.0

100.0

100.0

0.0

0.0

0.0

0.0

0.0

 

  1. Antibiotic Sensitivity Pattern – Panel 2

Organism

Vancomycin

Clindamycin

Rifampicin

Cotrimoxazole

Oxacillin

Cefoxitin

CONS

0.0

0.0

0.0

0.0

0.0

100.0

Staphylococcus aureus (MRSA)

100.0

0.0

100.0

0.0

0.0

100.0

Streptococcus species

100.0

0.0

0.0

0.0

0.0

0.0

 

Table: 9 Antifungal Susceptibility Pattern in Fungal UTI (%)

  1. Antifungal Resistance Pattern

Organism

Amphotericin B

Fluconazole

Voriconazole

Caspofungin

Flucytosine

Micafungin

Candida tropicalis

0.0

0.0

0.0

0.0

0.0

0.0

  1. Antifungal Sensitivity Pattern

Organism

Amphotericin B

Fluconazole

Voriconazole

Caspofungin

Flucytosine

Micafungin

Candida tropicalis

100.0

100.0

100.0

100.0

100.0

100.0

 

DISCUSSION

Urinary tract infection remains a significant cause of morbidity in the pediatric population, and the present prospective observational study provides valuable insights into the epidemiology, clinical presentation, microbiological spectrum, and antimicrobial susceptibility patterns of pediatric UTIs in a tertiary care hospital in South India.

 

Demographic Profile

In the present study, the majority of cases were observed in children aged 1–5 years (55.9%), followed by those above 5 years (22.5%) and infants below one year (21.6%). Similar age distributions have been reported in previous Indian and international studies, where toddlers and preschool children constituted the most affected age group due to increased exposure, immature immunity, and toilet training–related voiding dysfunctions [14,15]. A male predominance (61.8%) was observed in our study, which contrasts with the female preponderance reported in older children but aligns with findings in infants and young boys where congenital urinary anomalies and uncircumcised status increase susceptibility [16].

 

Clinical Presentation

Fever was the most common presenting symptom (59.8%), followed by dysuria (52.9%), vomiting (42.1%), irritability (39.2%), and poor feeding (36.3%). These findings are consistent with earlier studies emphasizing that fever remains the most reliable indicator of UTI in young children, while urinary symptoms are more frequently observed in older children [17,18]. The presence of non-specific symptoms such as irritability, vomiting, and poor feeding highlights the diagnostic challenge of pediatric UTIs and reinforces the importance of urine culture in febrile children without an obvious source of infection.

 

Upper and Lower UTI Distribution

Lower UTIs accounted for 62.7% of cases, while upper UTIs constituted 37.2%, indicating a predominance of cystitis over pyelonephritis. Similar distributions have been reported by Shaikh et al. and Sood et al., who noted that lower UTIs are more common but upper UTIs carry a higher risk of renal scarring and long-term complications [19,20]. Male predominance was more evident in upper UTIs in the younger age group, possibly due to underlying anatomical abnormalities.

 

 

Risk Factors

Constipation (39.2%) and bowel bladder dysfunction (26.4%) emerged as significant risk factors, particularly in children above 1 year of age. The strong association between constipation, bladder dysfunction, and UTIs has been well documented, with fecal retention leading to bladder compression, incomplete voiding, and urinary stasis [21]. Diarrhea preceding UTI was significantly associated with infants (<1 year), which may be attributed to perineal contamination and poor hygiene practices [22]. Posterior urethral valve was identified exclusively in male infants, underscoring the importance of evaluating congenital anomalies in recurrent or severe UTIs.

 

Ultrasonography Findings

Abnormal ultrasonography findings were observed in 32.4% of cases, with cystitis being the most common abnormality followed by hydroureteronephrosis. Comparable rates have been reported in similar hospital-based studies, emphasizing the role of ultrasonography as a non-invasive screening tool for detecting structural abnormalities and guiding further evaluation [23].

 

Microbiological Profile

Escherichia coli was the predominant uropathogen (45.1%), followed by Klebsiella pneumoniae (17.6%) and carbapenem-resistant E. coli (11.8%). These findings are consistent with global and Indian literature, where E. coli remains the leading cause of pediatric UTIs due to its virulence factors, including adhesins and biofilm formation [24,25]. The notable proportion of CRE isolates in our study is concerning and reflects the growing burden of antimicrobial resistance in tertiary care settings.

 

Gram-positive organisms accounted for a smaller proportion of infections, with Enterococcus species being the most common among them. Similar trends have been observed in recent studies, suggesting a gradual rise in Gram-positive uropathogens, particularly in hospitalized and catheterized patients [26].

 

Antimicrobial Resistance Patterns

High resistance rates were observed among Gram-negative isolates to commonly used antibiotics such as ampicillin, ceftriaxone, cefotaxime, ciprofloxacin, and cotrimoxazole. E. coli showed resistance exceeding 80% to third-generation cephalosporins and fluoroquinolones, which aligns with reports from other Indian centers [27,28]. The high resistance to oral antibiotics traditionally used for empirical therapy raises serious concerns regarding treatment failures and highlights the need for periodic surveillance.

 

Carbapenem resistance among E. coli (CRE) isolates was alarmingly high, limiting therapeutic options. Similar rising trends of carbapenem resistance have been documented across India, attributed to indiscriminate antibiotic use and lack of robust antimicrobial stewardship programs [29].

 

Antimicrobial Sensitivity Patterns

Amikacin, gentamicin, nitrofurantoin, piperacillin–tazobactam, and carbapenems demonstrated better sensitivity profiles against most Gram-negative isolates. Nitrofurantoin retained good activity against E. coli, supporting its role as a first-line agent for uncomplicated lower UTIs [30]. Gram-positive isolates, particularly Enterococcus species, showed excellent sensitivity to linezolid, vancomycin, teicoplanin, and daptomycin, consistent with earlier studies [31].

 

Fungal UTI

All Candida tropicalis isolates demonstrated 100% sensitivity to antifungal agents tested, including amphotericin B, azoles, and echinocandins. This finding is reassuring and comparable with previous pediatric studies, although continued vigilance is necessary due to emerging antifungal resistance reported in other regions [32].

 

Clinical Implications

The findings of this study emphasize the importance of culture-guided therapy in pediatric UTIs, given the high levels of antimicrobial resistance. Empirical treatment protocols should be revised periodically based on local antibiograms to prevent misuse of broad-spectrum antibiotics and curb the rise of multidrug-resistant organisms.

 

CONCLUSION

This study demonstrates that pediatric urinary tract infections are predominantly lower UTIs, with Escherichia coli as the most common causative organism. A substantial proportion of isolates showed resistance to commonly used empirical antibiotics, indicating a growing burden of antimicrobial resistance. Better sensitivity to nitrofurantoin, aminoglycosides, and higher-end antibiotics highlights the importance of culture-guided therapy. Early diagnosis, identification of underlying risk factors, and adherence to antimicrobial stewardship principles are essential to improve clinical outcomes and prevent the emergence of resistant uropathogens in children.

 

REFERENCES

  1. Shaikh N, Morone NE, Bost JE, Farrell MH. Prevalence of urinary tract infection in childhood: A meta-analysis. Pediatr Infect Dis J. 2008;27(4):302–308.
  2. Stein R, Dogan HS, Hoebeke P, et al. Urinary tract infections in children: EAU/ESPU guidelines. Eur Urol. 2015;67(3):546–558.
  3. Smellie JM, Normand IC, Katz G. Children with urinary infection: A comparison of those with and without vesicoureteric reflux. Kidney Int. 1981;20(6):717–722.
  4. Roberts KB. Urinary tract infection in infants and children. Pediatrics. 2011;128(3):595–610.
  5. Hoberman A, Charron M, Hickey RW, et al. Imaging studies after a first febrile urinary tract infection in young children. N Engl J Med. 2003;348(3):195–202.
  6. Zorc JJ, Kiddoo DA, Shaw KN. Diagnosis and management of pediatric urinary tract infections. Clin Microbiol Rev. 2005;18(2):417–422.
  7. Bitsori M, Galanakis E. Pediatric urinary tract infections: Diagnosis and treatment. Expert Rev Anti Infect Ther. 2012;10(10):1153–1164.
  8. Logan LK, Renschler JP, Gandra S, Weinstein RA, Laxminarayan R. Carbapenem-resistant Enterobacteriaceae in children, United States, 1999–2012. Emerg Infect Dis. 2015;21(11):2014–2021.
  9. World Health Organization. Global action plan on antimicrobial resistance. WHO; 2015.
  10. Kaur N, Sharma S, Malhotra S, Madan P, Hans C. Urinary tract infection: Aetiology and antimicrobial resistance pattern in infants from a tertiary care hospital in North India. J Glob Infect Dis. 2014;6(2):54–57.
  11. Loening-Baucke V. Urinary incontinence and urinary tract infection and their resolution with treatment of chronic constipation of childhood. Pediatrics. 1997;100(2):228–232.
  12. Chang SJ, Yang SS. Persistent daytime urinary incontinence in children. Nat Rev Urol. 2013;10(3):167–177.
  13. Subcommittee on Urinary Tract Infection, American Academy of Pediatrics. Urinary tract infection: Clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children aged 2 to 24 months. Pediatrics. 2011;128(3):595–610.
  1. Jodal U, Smellie JM. Epidemiology of childhood urinary tract infection. Pediatr Nephrol. 1992;6(1):85–90.
  2. Sood A, Penna FJ, Eleswarapu S, et al. Incidence, admission rates, and economic burden of pediatric emergency department visits for urinary tract infection. Pediatrics. 2015;135(5):e1169–e1178.
  3. Wiswell TE. The prepuce, urinary tract infections, and the consequences. Pediatrics. 2000;105(4):860–862.
  4. Hoberman A, Wald ER. Urinary tract infections in young febrile children. Pediatr Infect Dis J. 1997;16(1):11–17.
  5. Shaw KN, Gorelick M, McGowan KL, et al. Prevalence of urinary tract infection in febrile young children in the emergency department. Pediatrics. 1998;102(2):e16.
  6. Shaikh N, Ewing AL, Bhatnagar S, Hoberman A. Risk of renal scarring in children with a first urinary tract infection: A systematic review. Pediatrics. 2010;126(6):1084–1091.
  7. Sood A, Sharma S, Gupta S. Upper versus lower urinary tract infection in children. Indian J Pediatr. 2012;79(7):874–879.
  8. Loening-Baucke V. Chronic constipation in children. Gastroenterology. 1993;105(5):1557–1564.
  9. Hellström A, Hanson E, Hansson S, et al. Association between urinary symptoms at 7 years old and previous urinary tract infection. Arch Dis Child. 1991;66(2):232–234.
  10. Riccabona M. Imaging in childhood urinary tract infection. Nat Rev Urol. 2015;12(9):507–521.
  11. Foxman B. Epidemiology of urinary tract infections: Incidence, morbidity, and economic costs. Am J Med. 2002;113(Suppl 1A):5S–13S.
  12. Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: Epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015;13(5):269–284.
  13. Linhares I, Raposo T, Rodrigues A, Almeida A. Frequency and antimicrobial resistance patterns of bacteria implicated in community urinary tract infections. BMC Infect Dis. 2013;13:19.
  14. Mandal J, Acharya NS, Buddhapriya D, et al. Antibiotic resistance pattern of uropathogens in a tertiary care hospital. Indian J Med Microbiol. 2012;30(4):427–431.
  15. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis. Clin Infect Dis. 2011;52(5):e103–e120.
  16. Logan LK, Weinstein RA. The epidemiology of carbapenem-resistant Enterobacteriaceae. Curr Opin Infect Dis. 2017;30(1):56–65.
  17. Sanchez GV, Master RN, Karlowsky JA, Bordon JM. In vitro antimicrobial resistance of urinary coli isolates. Antimicrob Agents Chemother. 2012;56(4):2181–2183.
  18. Arias CA, Murray BE. Enterococcus species, Streptococcus bovis group, and Leuconostoc species. In: Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 9th ed.
  19. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis. Clin Microbiol Rev. 2007;20(1):133–163.
Recommended Articles
Original Article Open Access
Efficacy of Ormeloxifene Versus Norethisterone in Selected Group of Patients with Abnormal Uterine Bleeding – A Comparative Study
2026, Volume-7, Issue 1 : 530-535
Original Article Open Access
Challenging the Rare: Surgical Outcomes of Cerebral Alveolar Hydatid Cysts Caused by Echinococcus Multilocularis - A Case Series and Technical Review
2026, Volume-7, Issue 1 : 498-506
Original Article Open Access
VACTERL Association with High-Type Imperforate Anus, Crossed Fused Renal Ectopia, and Hexadactyly in a Neonate: A Case Report
2026, Volume-7, Issue 1 : 507-513
Original Article Open Access
Impact of Psychiatric Comorbidities On Quality of Life and Disease Severity in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease: A Cross-Sectional Study from India
2026, Volume-7, Issue 1 : 549-555
International Journal of Medical and Pharmaceutical Research journal thumbnail
Volume-7, Issue 1
Citations
13 Views
9 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
Creative Commons Attribution License Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
facebook twitter linkedin mendeley research-gate
© Copyright | International Journal of Medical and Pharmaceutical Research | All Rights Reserved